OSE IMMUNO overview

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine bispecific technology. CLEC-1, a novel immune checkpoint target. NANTES, France – April 3, 2025, 6:00 p.m. CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , a biotech company dedicated to developing first-in-class therapies in immuno-oncology and immuno-inflammation, today announced that the latest preclinical data on its novel...

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update Total income of €83.4 million. Cash level of €64.2 million 1 as of December 31, 2024, ensuring financial visibility until Q1 2027 Three strategic agreements signed: licensing and collaboration with AbbVie (worth up to $713 million), and anti-SIRP α program expansions (worth up to € 1.1 billion), plus a purchase asset agreement with Boehringer Ingelheim. € 8.4 million in non-dilutive public...

OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs) to discuss the latest clinical trial results and scientific data on Lusvertikimab, particularly its positive outcomes in treating ulcerative colitis (UC). The webinar included insights from: Prof Laurent Peyrin-Biroulet , Professor of Gastroenterology, Nancy University...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO Lusvertikimab achieved statistical significance on the primary and secondary endpoints in moderate to severe active ulcerative colitis (UC) patients during the 10-week induction period of treatment in the randomized, double-blind CoTikiS Phase 2 study. These results were presented in the Top 10 congress highlights oral plenary session at ECCO 2025....

OSE Immunotherapeutics Presents Positive Preclinical Data on Combination of Anti-IL-7 Receptor Lusvertikimab in Chronic Colitis In Oral Presentation at 20 th Congress of ECCO NANTES, France – February 20, 2025, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today presented positive preclinical data on the combination of anti-IL-7 receptor (IL-7R) with anti-IL-12/23 monoclonal antibody (mAb) in chronic colitis at the 20 th Congress of ECCO (European Crohn’s and...

OSE Immunotherapeutics Presents Three Abstracts for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France - January 28 2025, – 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , shares details of the three scientific abstracts on its anti-IL-Receptor (IL-7R) Lusvertikimab, which is in clinical development for ulcerative colitis. These abstracts will be presented in Oral Presentation, Digital Oral Presentation and Poster...

OSE Immunotherapeutics Appoints Dr. Sonya Montgomery as Chief Development Officer NANTES, France, January 13, 2025 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) , today announced the appointment of Dr. Sonya Montgomery as Chief Development Officer. Sonya will serve on the OSE Immunotherapeutics Executive Committee in a strategic move that will enhance the company’s development capabilities. Dr. Montgomery brings over two decades of experience leading R&D...

A clinical abstract on the induction results from the CoTikiS Phase 2 trial of anti-IL-7 Receptor Lusvertikimab in Ulcerative Colitis accepted for Oral Presentation and selected amongst the Top 10 oral abstracts for 20 th Congress of European Crohn’s and Colitis Organization (ECCO) Highlights. Research highlights OSE Immunotherapeutics’ continued commitment to advancing the treatment and management of IBD. NANTES, France, December 18, 2024 – 6:00pm CET - OSE Immunotherapeutics SA (ISIN:...